Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL |
| |
Authors: | Baohai Shao |
| |
Affiliation: | Division of Metabolism, Endocrinology and Nutrition, Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, WA 98109, USA |
| |
Abstract: | The mechanisms that deprive HDL of its cardioprotective properties are poorly understood. One potential pathway involves oxidative damage of HDL proteins by myeloperoxidase (MPO) a heme enzyme secreted by human artery wall macrophages. Mass spectrometric analysis demonstrated that levels of 3-chlorotyrosine and 3-nitrotyrosine - two characteristic products of MPO - are elevated in HDL isolated from patients with established cardiovascular disease. When apolipoprotein A-I (apoA-I), the major HDL protein, is oxidized by MPO, its ability to promote cellular cholesterol efflux by the membrane-associated ATP-binding cassette transporter A1 (ABCA1) pathway is diminished. Biochemical studies revealed that oxidation of specific tyrosine and methionine residues in apoA-I contributes to this loss of ABCA1 activity. Another potential mechanism for generating dysfunctional HDL involves covalent modification of apoA-I by reactive carbonyls, which have been implicated in atherogenesis and diabetic vascular disease. Indeed, modification of apoA-I by malondialdehyde (MDA) or acrolein also markedly impaired the lipoprotein's ability to promote cellular cholesterol efflux by the ABCA1 pathway. Tandem mass spectrometric analyses revealed that these reactive carbonyls target specific Lys residues in the C-terminus of apoA-I. Importantly, immunochemical analyses showed that levels of MDA-protein adducts are elevated in HDL isolated from human atherosclerotic lesions. Also, apoA-I co-localized with acrolein adducts in such lesions. Thus, lipid peroxidation products might specifically modify HDL in vivo. Our observations support the hypotheses that MPO and reactive carbonyls might generate dysfunctional HDL in humans. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010). |
| |
Keywords: | ABCA1, ATP-binding cassette transporter A1 ABCG1, ATP-binding cassette transporter G1 AGE, advanced glycation end products ALE, advanced lipoxidation end products apoA-I, apolipoprotein A-I BHK, baby hamster kidney CAD, coronary artery disease DHP-lysine, dihydropyridine-lysine DTPA, diethylenetriaminepentaacetic acid HDL, high-density lipoproteins HNE, 4-hydroxynonenal HOCl, hypochlorous acid H2O2, hydrogen peroxide LCAT, lecithin:cholesterol acyltransferase LC-MS/MS, liquid chromatography-tandem mass spectrometry LDL, low-density lipoprotein Lys-MDA-Lys, Lys-1-amino-3-iminopropene-Lys Met(O), methionine sulfoxide MDA, malondialdehyde MPO, myeloperoxidase MP-lysine, Nε-(3-methylpyridinium)lysine MS, mass spectrometry NO, nitric oxide NO2 0" alt=" radical dot" src=" http://cdn.els-cdn.com/sd/entities/rad" class=" glyphImg" >, nitrogen dioxide radical ONOO&minus , peroxynitrite PilB, methionine sulfoxide reductase SR-B1, scavenger receptor B1 SUV, single unilamellar vesicles WT, wild type Y192F, Tyr192Phe apoA-I mutant |
本文献已被 ScienceDirect 等数据库收录! |
|